2021年までのまとめ 国際学会 (International conference)

72) Tanaka K, Kanazawa I, Richards JB, Goltzman D, Sugimoto T. Modulators of Fam210a and effects of Fam210a on myoblastic differentiation and degradation. American Society for Bone and Mineral Research 2018 Annual Meeting, America (Orlando), September 20-23, 2019
71) Kanazawa I, Adachi N, Tanaka K, Takeno A, Notsu M, Tanaka S, Sugimoto T. Effects of advanced glycation end products, high glucose, and insulin-like growth factor-I on myoblastic differentiation and apoptosis in C2C12 cells. American Society for Bone and Mineral Research 2018 Annual Meeting, America (Orlando), September 20-23, 2019
70) Kanazawa I, Adachi N, Tanaka K, TakenoA, Notsu M, Tanaka S, Sugimoto T. Insulin-like growth factor-I protects against the detrimental effects of advanced glycation end products and high glucose in myoblastic C2C12 cells. American Diabetes Association 79th Scientific Sessions, America (San Francisco), June 7-11, 2019
69) Kanazawa I. Effects of advanced glycation end products and homocysteine on apoptosis and expression of sclerostin and RANKL in osteocyte-like MLO-Y4 cells. Asia Pacific Bone Academy 2018, Taipei (Taiwan), November 9-11, 2018
68) Kanazawa I, Notsu M, Tanaka K, Sugimoto T. Association of body mass index with the risk of vertebral fractures in patients with type 2 diabetes mellitus. 54th Annual Meeting of the European Association for the Study of Diabetes, Berlin (Germany), October 1-5, 2018
67) Kanazawa I, Notsu M, Tanaka K, Sugimoto T. Overweight and underweight are risk factors for vertebral fractures in patients with type 2 diabetes mellitus. American Society for Bone and Mineral Research 2018 Annual Meeting, Canada (Montreal), September 28-October 1, 2018
66) Tanaka K, Xue Y, Nguyen-Yamamoto L, Morris JA, Kanazawa I, Sugimoto T, Wing SS, Richards JB, Goltzman D. Fam210a is a novel determinant of bone and muscle. American Society for Bone and Mineral Research 2018 Annual Meeting, Canada (Montreal), September 28-October 1, 2018
65) Kanazawa I, Takeno A, Tanaka KI, Yamane Y, Sugimoto T. Osteoporosis and vertebral fracture are associated with deterioration of ADL and QOL in patients with type 2 diabetes mellitus independently of other diabetic complications. 53th Annual Meeting of the European Association for the Study of Diabetes, Lisbon (Portugal), September 11-15, 2017
64) Miyake H, Kanazawa I, SUgimoto T. Low skeletal muscle mass is an increased risk of all-cause mortality in patients with type 2 diabetes mellitus. 53th Annual Meeting of the European Association for the Study of Diabetes, Lisbon (Portugal), September 11-15, 2017
63) Kanazawa I, Takeno A, Tanaka KI, Notsu M, Sugimoto T. The in vivo roles of osteoblast AMP-activated protein kinase in skeletal development. American Society for Bone and Mineral Research 2017 Annual Meeting, America (Denver), September 8-11, 2017
62) Takeno A, Kanazawa I, Notsu M, Tanaka KI, Sugimoto T. Effects of glucose uptake inhibition by phloretin on expressions of RANKL and osteocalcin in osteocytic MLO-Y4-A2 cells. American Society for Bone and Mineral Research 2017 Annual Meeting, America (Denver), September 8-11, 2017
61) Kanazawa I, Miyake H, Sugimoto T. Association of bone turnover markers, bone mineral density, and prevalent vertebral fracture with all-cause mortality in patients with type 2 diabetes mellitus. Joint meeting of the Australian & New Zealand Bone & Mineral Society & the International Federation of Musculoskeletal Research Societies in conjunction with the Japanese Society for Bone & Mineral Research, Australia (Brisbane), June 17-21, 2017
60) Kanazawa I, Takeno A, Tanaka KI, Notsu M, Sugimoto T. Osteoblast AMP-activated protein kinase regulates skeletal development in vivo. Joint meeting of the Australian & New Zealand Bone & Mineral Society & the International Federation of Musculoskeletal Research Societies in conjunction with the Japanese Society for Bone & Mineral Research, Australia (Brisbane), June 17-21, 2017
59) Takeno A, Kanazawa I, Notsu M, Tanaka KI, Sugimoto T. Roles of glucose transporter in expressions of receptor activator of nuclear factor-kappa B ligand (RANKL) and osteocalcin in osteocytic MLO-Y4-A2 cells. Joint meeting of the Australian & New Zealand Bone & Mineral Society & the International Federation of Musculoskeletal Research Societies in conjunction with the Japanese Society for Bone & Mineral Research, Australia (Brisbane), June 17-21, 2017
58) Tanaka S, Kanazawa I, Sugimoto T. Association of leukocyte subtype counts with chronic inflammation and atherosclerosis in type 2 diabetes mellitus. 11th International Diabetes Federation Western Pacific Region Congress and 8th Scientific Meeting of the Asian Association for the Study of Diabetes, Taiwan (Taipei), October 27-30, 2016
57) Miyake H, Kanazawa I, Sugimoto T. Low skeletal muscle mass is associated with increased mortality in postmenopausal women with type 2 diabetes mellitus. 11th International Diabetes Federation Western Pacific Region Congress and 8th Scientific Meeting of the Asian Association for the Study of Diabetes, Taiwan (Taipei), October 27-30, 2016
56) Kanazawa I, Tanaka KI, Notsu M, Tanaka S, Kiyohara N, Koike S, Yamane Y, Tada Y, Sasaki M, Yamauchi M, Sugimoto T. Long-term efficacy and safety of add-on therapy of vildagliptin in type 2 diabetes mellitus with insulin treatment. 11th International Diabetes Federation Western Pacific Region Congress and 8 th Scientific Meeting of the Asian Association for the Study of Diabetes, Taiwan (Taipei), October 27-30, 2016
55) Takeno A, Kanazawa I, Tanaka KI, Notsu M, Yokomoto-Umakoshi M, Sugimoto T. Simvastatin rescues homocysteine-induced apoptosis of osteocytic MLO-Y4 cells by decreasing the expressions of NADPH oxidase 1 (Nox1) and Nox2. American Society for Bone Mineral Research 2016 Annual Meeting, America (Atlanta), September 16-19, 2016
54) Kanazawa I, Yokomoto-Umakoshi M, Takeno A, Tanaka KI, Notsu M, Sugimoto T. Activation of AMP-activated protein kinase decreases RANKL expression and increases sclerostin expression by inhibiting the mevalonate pathway in osteocytic MLO-Y4 cells. American Society for Bone Mineral Research 2016 Annual Meeting, America (Atlanta), September 16-19, 2016
53) Miyazaki Y, Niino M, Kanazawa I, Suzuki M, Mizuno M, Hisahara S, Fukazawa T, Takahashi E, Amino I, Ochi R, Minami N, Fujiki N, Doi S, Kikuchi S. Fingolimod suppresses bone resorption in patients with multiple sclerosis. American Academy of Neurology 2016 Annual Meeting, Canada (Vancouver), April 15-21, 2016
52) Kanazawa I, Sugimoto T. Prehypertension increases the risk of atherosclerosis in type 2 diabetes mellitus. The 4th International Conference on Prehypertension, Hypertension & Cardio Metabolic Syndrome, Italy (Venice), March 3-6, 2016
51) Tanaka S, Kanazawa I, Sugimoto T. Circulating monocyte count is positively associated with chronic inflammation and atherosclerosis in type 2 diabetes mellitus. The 4th International Conference on Prehypertension, Hypertension & Cardio Metabolic Syndrome, Italy (Venice), March 3-6, 2016
50) Miyake H, Kanazawa I, Sugimoto T. Macroalbuminuria increases all-cause mortality in Japanese patients with type 2 diabetes mellitus. International Diabetes Federation World Diabetes Congress 2015, Canada (Vancouver), November 30-December 4, 2015
49) Tanaka S, Kanazawa I, Sugimoto T. Peripheral neuropathy increases the risk of atherosclerosis in type 2 diabetes mellitus. International Diabetes Federation World Diabetes Congress 2015, Canada (Vancouver), November 30-December 4, 2015
48) Kanazawa I, Tanaka KI, Yamaguchi T, Yano S, Kaji H, Sugimoto T. Active vitamin D possesses beneficial effects on the interaction between muscle and bone. American Society for Bone and Mineral Research 2015 Annual Meeting, America (Seattle), October 9-12, 2015
47) Takeno A, Kanazawa I, Tanaka KI, Notsu M, Yokomoto M, Yamaguchi T, Sugimoto T. Activation of AMP-activated protein kinase protects against homocysteine-induced apoptosis of osteocytic MLO-Y4 cells by regulating the expressions of NADPH oxidase 1 (Nox1) and Nox2. American Society for Bone and Mineral Research 2015 Annual Meeting, America (Seattle), October 9-12, 2015
46) Kanazawa I, Takeno A, Tanaka KI, Notsu M, Yokomoto M, Yamaguchi T, Sugimoto T. Metformin protects against homocysteine-induced apoptosis of osteocytic MLO-Y4 cells by activation of AMP-activated protein kinase. 51th Annual Meeting of the European Association for the Study of Diabetes. Sweden (Stockholm), September 14-18, 2015
45) Tanaka S, Kanazawa I, Notsu M, Sugimoto T. Visceral fat obesity and metabolic syndrome increase serum DPP-4 levels in type 2 diabetes mellitus. 51th Annual Meeting of the European Association for the Study of Diabetes. Sweden (Stockholm), September 14-18, 2015
44) Miyake H, Kanazawa I, Sugimoto T. Severe vertebral fracture and low osteocalcin level increase the mortality in postmenopausal women with type 2 diabetes mellitus. 51th Annual Meeting of the European Association for the Study of Diabetes. Sweden (Stockholm), September 14-18, 2015
43) Tanaka S, Kanazawa I, Notsu M, Sugimoto T. The effect of pioglitazone and metformin on serum DPP-4 levels in type 2 diabetes mellitus. 10th International Diabetes Federation Western Pacific Region Congress and 6th Scientific Meeting of the Asian Association for the Study of DIabetes, Singapore, November 21-24, 2014
42) Miyake H, Kanazawa I, Sugimoto T. Low levels of serum insulin-like growth factor-I increase mortality in patients with type 2 diabetes mellitus. 10th International Diabetes Federation Western Pacific Region Congress and 6th Scientific Meeting of the Asian Association for the Study of DIabetes, Singapore, November 21-24, 2014
41) Kanazawa I. Low level of serum IGF-I increases the risk of osteoporotic fracture in postmenopausal women with type 2 diabetes mellitus. 5th World Congress on Diabetes & Metabolism, America (Las Vegas), November 3-5, 2014
40) Miyake H, Kanazawa I, Yamaguchi T, Sugimoto T. Low levels of serum insulin-like growth factor-I increase the risk of osteoporotic fracture and mortality in postmenopausal women with type 2 diabetes mellitus. 50th Annual Meeting of the European Association for the Study of Diabetes, Austria (Vienna), September 15-19, 2014
39) Yamaguchi T, Notsu M, Okazaki K, Tanaka K, Ogawa N, Kanazawa I, Sugimoto T. Advanced glycation end products inhibit the mineralization of marrow stromal cells by binding the receptor for AGEs and increasing TGF-b expression and secretion. The 41st European Calcified Tissue Society Congress. Czech Republic (Prague), May 17-20, 2014
38) Yamaguchi T, Tada Y, Kanazawa I, Morita M, Furuya N, Yamamoto M, Yamauchi M, Sugimoto T. Intensive glycemic control improved the excretion of urine mineral ions in type 2 diabetes mellitus. The 24th annual scientific meeting of Australian and New Zealand Bone and Mineral Society. New Zealand (Queenstown), September 7-10, 2014
37) Tada Y, Yamaguchi T, Tanaka KI, Tanaka S, Notsu M, Miyake H, Morita M, Ogawa N, Kanazawa I, Yamamoto M, Sugimoto T. Intensive glycemic control improved the excretion of urine mineral irons in type 2 diabetes mellitus. IDF World Diabetes Congress Melbourne, Australia (Melbourne), December 2-6, 2013
36) Notsu M, Yamaguchi T, Okazaki K, Tanaka KI, Ogawa N, Kanazawa I, Sugimoto T. Advanced glycation end products inhibit the mineralization of mouse stromal ST2 cells by binding the receptor for AGEs and increasing TGFb expression and secretion. American Society for Bone and Mineral Research 2013 Annual Meeting, America (Baltimore), October 4-7, 2013
35) Tanaka KI, Kaji H, Kanazawa I, Canaff L, Hendy GN, Sugimoto T. Role of the osteoinductive factors, Tmem119, BMP-2 and the ER stress response PERK-eIF2a-ATF4 pathway in the commitment of myoblastic into osteoblastic cells. American Society for Bone and Mineral Research 2013 Annual Meeting, America (Baltimore), October 4-7, 2013
34) Kanazawa I, Canaff L, Angrula A, Li J, Murshed M, Hendy GN. Role of menin in bone development. American Society for Bone and Mineral Research 2013 Annual Meeting, America (Baltimore), October 4-7, 2013
33) Kanazawa I, Canaff L, Murshed M, Hendy GN. Menin is required to maintain bone mass in older mice. 2nd Joint Meeting of the International Bone and Mineral Society and The Japanese Society for Bone and Mineral Research, Japan (Kobe), May 28-June 1, 2013
32) Notsu M, Yamaguchi T, Okazaki K, Tanaka K, Ogawa N, Kanazawa I, Sugimoto T. Advanced glycation end product 3 (AGE3) suppresses the mineralization of mouse stromal ST2 cells by increasing TGF-beta expression and secretion. 2nd Joint Meeting of the International Bone and Mineral Society and The Japanese Society for Bone and Mineral Research, Japan (Kobe), May 28-June 1, 2013
31) Tanaka K, Yamaguchi T, Kaji H, Kanazawa I, Sugimoto T. The role of endoplasmic reticulum stress in bone formation suppressed by advanced glycation end products. 2nd Joint Meeting of the International Bone and Mineral Society and The Japanese Society for Bone and Mineral Research, Japan (Kobe), May 28-June 1, 2013
30) Kanazawa I, Canaff L, Angrula A, Li , Murshed M, Hendy GN. Role of menin in bone development. European Congress on Osteoporosis and Osteoarthritis (ESCEO13-IOF), Italy (Rome), April 17-20, 2013
29) Kanazawa I, Canaff L, Angrula A, Li , Murshed M, Hendy GN. Role of menin in bone development. Endocrine Retreat in McGill University, Canada (Montreal), April 4, 2013
28) Kanazawa I, Yamaguchi T, Yamauchi M, Yamamoto M, Yano S, Sugimoto T. Effects of pioglitazone on bone mineral density, bone markers, and vertebral fractures in type 2 diabete mellitus. 9th International Diabetes Federation Western Pacific Region Congress and 4th Scientific Meeting of the Asian Association for the Study of DIabetes, Japan (Kyoto), November 22-27, 2012
27) Kanazawa I, Canaff L, Murshed M, Geoffrey GN. Menin is required to maintain bone mass in older mice. 13th International Workshop on Multiple Endocrine Neoplasia, Belgium (Liege), September 5-8, 2012
26) Kanazawa I, Yamaguchi T, Yamauchi M, Yamamoto M, Yano S, Sugimoto T. The effects of pioglitazone, a PPAR-r agonist, on bone turnover markers, bone mineral density, and vertebral fractures in type 2 diabete mellitus. 22nd Annual Scientific meeting of Australian & New Zealand Bone & Mineral Society and 1st Asia-Pacific Bone and Mineral Research Meeting, Australia (Perth), September 2-5, 2012
25) Kanazawa I, Nayak G, Canaff L, Murshed M, Hendy GN. Reduced Bone Mass in Mice Lacking the Men1 Gene in Osteoblasts. The second Scientific Meeting of the Asian Federation of Osteoporosis Societies, Japan (Kobe), November 3-4, 2011
24) Kanazawa I, Nayak G, Canaff L, Murshed M, Hendy GN. Reduced Bone Mass in Mice Lacking the Men1 Gene in Osteoblasts. The New Therapeutics Targets & Diagnostics in Musculoskeletal Disorders, Canada (Montreal), October 28, 2011
23) Kanazawa I, Nayak G, Canaff L, Murshed M, Hendy GN. Reduced Bone Mass in Mice Lacking the Men1 Gene in Osteoblasts. 34th Annual Meeting of the Society for Craniofacial Genetics and Developmental Biology, Canada (Montreal), October 11, 2011
22) Tada Y, Yano S, Okazaki K, Ogawa N, Morita M, Kanazawa I, Yamaguchi T, Sugimoto T. Advanced glycation end-products-induced vascular calcification is mediated by oxidative stress: functional roles of NAD(P)H-oxidase. American Society for Bone and Mineral Research 33nd Annual Meeting, America (San Diego), September 16-20, 2011
21) Kanazawa I, Nayak G, Canaff L, Murshed M, Hendy GN. Reduced accumulation of bone in mice lacking the Men1 gene in osteoblasts. American Society for Bone and Mineral Research 33nd Annual Meeting, America (San Diego), September 16-20, 2011
20) Kanazawa I, Nayak G, Canaff L, Murshed M, Hendy GN. Reduced bone mass in mice lacking the Men1 gene in osteoblasts. Fourth Fellows Forum on Metabolic Bone Diseases, America (San Diego), September 14-15, 2011
19) Kanazawa I, Nayak G, Canaff L, Murshed M, Hendy GN. Reduced accumulation of bone in mice lacking the Men1 gene in osteoblasts. Endocrine Retreat in McGill University, Canada (Montreal), May 24, 2011
18) Canaff L, Kanazawa I, Garfield N, Vautour L, Hendy GN. Menin missense mutants causing Multiple Endocrine Neoplasia type 1 (MEN1) that are targeted to the proteasome: restoration of expression and cell proliferation control by COOH-terminus of Hsp70-interacting protein (CHIP) siRNA. Endocrine Retreat in McGill University, Canada (Montreal), May 24, 2011
17) Yamaguchi T, Yamamoto M, Kanazawa I, Yamauchi M, Kurioka S, Yano S, Sugimoto T. Quantitative ultrasound of the calcaneus is not useful for assessing the risk of vertebral fractures in patients with type 2 diabetes. IOF Regionals Singapore’ 10 1st Asia-Pacific Osteoporosis Meeting, Singapore, December 10-13, 2010
16) Kanazawa I, Canaff L, Murshed M, Hendy GN. Generation of Col1a1-Men1 mice specifically overexpressing the tumor suppressor menin in osteoblasts. Human Cell Transformation Conference 2010, Canada (Montreal), October 20-21, 2010
15) Kanazawa I, Yamaguchi T, Tada Y, Yamamoto M, Yamauchi M, Yano S, Sugimoto T. Serum osteocalcin exerts beneficial effects on insulin sensitivity and secretion. American Society for Bone and Mineral Research 32nd Annual Meeting, Canada (Toronto), October 15-19, 2010
14) Kanazawa I, Canaff L, Murshed M and Hendy GN. Generation of Col1a1-Men1 mice specifically overexpressing the tumor suppressor menin in osteoblasts. Endocrine Retreat in McGill University, Canada (Montreal), May 13, 2010
13) Yamaguchi T, Kanazawa I, Yamamoto M, Yamauchi M, Yano S, Sugimoto T. Associations between components of the metabolic syndrome versus bone mineral density and vertebral fractures in patients with type 2 diabetes. American Society for Bone and Mineral Research 31th Annual Meeting, America (Denver), September 11-15, 2009
12) Takase H, Yano S, Yamaguchi T, Kanazawa I, Hayashi K, Sugimoto T, Yamauchi M, Yamamoto M. Parathyroid hormone up-regulates BMP-2 mRNA expression through mevalonate kinase inhibition in osteoblastic MC3T3-E1 cells. American Society for Bone and Mineral Research 31th Annual Meeting, America (Denver), September 11-15, 2009
11) Kurioka S, Kanazawa I, Morita M, Yamaguchi T, Sugimoto T: Long-term use of colestimide is effective against hyperglycemia and overweight in patients with type 2 diabetes. American Diabetes Association 69th Scientific Sessions, America (New Orleans), June 5-9, 2009
10) Morita M, Kurioka S, Tada Y, Takase H, Takaoka S, Kanazawa I, Yamamoto M, Yamaguchi T, Sugimoto T. Gastrointestinal Symptoms are Masked and Diminished by Autonomic Neuropathy in Patients with Type 2 Diabetes. American Diabetes Association 69th Scientific Sessions, America (New Orleans), June 5-9, 2009
9) Yamane Y, Yamaguchi T, Murase A, Tsumori M, Kanazawa I, Yamane T, Sugimoto T: Comparison of the effects of an L- and T-type calcium channel blocker (Benidipine) with an L-type dominant calcium channel blocker (Amlodipine) on hypertension and albuminemia in patients with type 2 diabetes. American Diabetes Association 69th Scientific Sessions, America (New Orleans), June 5-9, 2009
8) Yamaguchi T, Kanazawa I, Yamamoto M, Yamauchi M, Kurioka S, Yano S, Sugimoto T: Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in patients with type 2 diabetes.2nd Joint Meeting of the International Bone & Mineral Society and the Australian and New Zealand Bone and Mineral Society, Australia (Sydney), March 21-25, 2009
7) Yamaguchi T, Hayashi K, Yano S, Kanazawa I, Yamauchi M, Yamamoto M, Sugimoto T: BMP/Wnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: potential therapeutic targets for glucocorticoid-induced osteoporosis. 2nd Joint Meeting of the International Bone & Mineral Society and the Australian and New Zealand Bone and Mineral Society, Australia (Sydney), March 21-25, 2009
6) Kanazawa I, Yamaguchi T, Yano S, Hayashi K, Yamauchi M, Sugimoto T. Inhibition of the Mevalonate Pathway Rescues the Dexamethasone-Induced Suppression of the Mineralization of Osteoblastic cells. American Society for Bone and Mineral Research 30th Annual Meeting, Canada (Montreal), September 12-16, 2008
5) Hayashi K, Kurioka S, Kanazawa I, Takase H, Yamamoto M, Wada A, Kitagaki H, Oguro H, Nagai A, Bokura H, Yamaguchi S, Yamaguchi T, Sugimoto T. The Association of Cognitive Dysfunction with Hippocampal and Brain Atrophy in Japanese Elderly Patients with Type 2 Diabetes. American Diabetes Association 68th Scientific Sessions, America (San Francisco), June 6-10, 2008
4) Kanazawa I, Yamaguchi T, Yano S, Yamauchi M, Yamamoto M, Sugimoto T: AMP-kinase activator (AICAR) and Rho-kinase inhibitor (hydroxyfasudil) induce the differentiation and mineralization of osteoblastic MC3T3-E1 cells via inhibiting the mevalonate pathway and enhancing BMP-2 expression. American Society for Bone and Mineral Research 29th Annual Meeting, America (Honolulu), September 16-19, 2007
3) Kanazawa I, Yamaguchi T, Yano S, Yamamoto M, Yamauchi M, Sugimoto T: Adiponectin stimulates proliferation, differentiation and mineralization via the AMPK signaling pathway in MC3T3-E1.3rd IOF Asia-Pacific Regional Conference on Osteoporosis and 16th Annual Meeting of the Australian & New Zealand Bone & Mineral Society, Australia (Port Douglas), October 22-26, 2006
2) Sohmiya M, Kanazawa I, Kato Y. Effect of long-term administration of recombinant human GH on granulocyte colony stimulating factor (G-CSF) and neutrophils in patients with adult GH deficiency. 84th Annual Meeting of the Endocrine Society, America (San Francisco), June 19-22, 2002
1) Sohmiya M, Kanazawa I, Kato Y. Seasonal change of body composition and plasma glucose control in male patients with type 2 diabetes mellitus treated with insulin. 84th Annual Meeting of the Endocrine Society, America (San Francisco), June 19-22, 2002

Posting order
金沢一平 糖尿病と骨粗しょう症専門医からの提案